The prospect of “massive and immediate price erosion in the market for oral treatment of relapsing-remitting multiple sclerosis” if up to six generic fingolimods were launched at-risk in the US when a molecule patent protecting Novartis’ Gilenya expires in mid-August this year has persuaded a Delaware district judge to grant an preliminary injunction barring generic competition until a decision at trial.
Delaware District Judge Leonard Stark was not convinced by any of the three arguments brought by generics defendants including Accord...
